The identification ofstroma-mediated resistance in BRAF-mutant melanomas, through the secretion of hepatocytegrowth factor (HGF), therefore indicates a potential therapeutic strategy throughcombination treatment of RAF inhibitors and inhibition of the HGF activated pathway(Straussman et al., 2012). The gene discussed is BRAF; the disease is melanoma.